We have located links that may give you full text access.
Implications of Single-Vessel Runoff on Long Term Outcomes of Free Tissue Transfer for Lower Extremity Reconstruction.
Journal of Reconstructive Microsurgery 2023 September 27
BACKGROUND: Patients with complex lower extremity (LE) wounds and single-vessel LE runoff (1-VRO) are often considered for amputation. While more challenging, free tissue transfer (FTT) is a means for limb salvage. This study aims to demonstrate the feasibility of limb salvage with FTT in patients with 1-VRO.
METHODS: Patients undergoing FTT by a single surgeon between 2011 and 2021 were retrospectively reviewed. Data collected included demographics, wound characteristics, vascular status, and operative details. Patients were divided into cohorts based on 1- vs. 3-VRO of tibial vessel inflow. Outcomes of interest included postoperative complications such as flap necrosis, flap success, limb salvage, and ambulatory status.
RESULTS: A total of 188 patients underwent FTT to LE, with 25 patients (13.3%) having 1-VRO. Patients with 1-VRO had a comparable prevalence of diabetes (56.0% vs. 50.0%, p=0.569) and end-stage renal disease (8.0% vs. 3.7%, p=0.319). Osteomyelitis was more common in the 1-VRO group (80.0% vs. 60.1%, p=0.056). FTT donor sites and flap composition were similar between cohorts. At mean follow-up of 21.2 months (IQR 24.5: 5.6, 30.1 months), limb salvage rates were similar between cohorts (84.0% vs. 91.4%, p=0.241), with no significant differences in ambulatory status or mortality. Higher complication rates occurred in the 1-VRO cohort (48.0% vs. 21.5%, p=0.004), of which partial flap necrosis was more prevalent in the 1-VRO group (8.0% vs. 1.2%, p=0.029). There was no difference in flap success rates between groups (p=0.805). More post-flap angiograms were performed in the 1-VRO group (32.0% vs. 9.2%, p=0.001), but there was no difference in need for repeat percutaneous endovascular intervention between groups.
CONCLUSION: This study demonstrates that FTT reconstruction to the LE remains a reliable reconstruction option for limb-salvage in patients with single-vessel supply to the LE. Reliance on advanced perioperative management and patient optimization is effective at reducing negative outcomes.
METHODS: Patients undergoing FTT by a single surgeon between 2011 and 2021 were retrospectively reviewed. Data collected included demographics, wound characteristics, vascular status, and operative details. Patients were divided into cohorts based on 1- vs. 3-VRO of tibial vessel inflow. Outcomes of interest included postoperative complications such as flap necrosis, flap success, limb salvage, and ambulatory status.
RESULTS: A total of 188 patients underwent FTT to LE, with 25 patients (13.3%) having 1-VRO. Patients with 1-VRO had a comparable prevalence of diabetes (56.0% vs. 50.0%, p=0.569) and end-stage renal disease (8.0% vs. 3.7%, p=0.319). Osteomyelitis was more common in the 1-VRO group (80.0% vs. 60.1%, p=0.056). FTT donor sites and flap composition were similar between cohorts. At mean follow-up of 21.2 months (IQR 24.5: 5.6, 30.1 months), limb salvage rates were similar between cohorts (84.0% vs. 91.4%, p=0.241), with no significant differences in ambulatory status or mortality. Higher complication rates occurred in the 1-VRO cohort (48.0% vs. 21.5%, p=0.004), of which partial flap necrosis was more prevalent in the 1-VRO group (8.0% vs. 1.2%, p=0.029). There was no difference in flap success rates between groups (p=0.805). More post-flap angiograms were performed in the 1-VRO group (32.0% vs. 9.2%, p=0.001), but there was no difference in need for repeat percutaneous endovascular intervention between groups.
CONCLUSION: This study demonstrates that FTT reconstruction to the LE remains a reliable reconstruction option for limb-salvage in patients with single-vessel supply to the LE. Reliance on advanced perioperative management and patient optimization is effective at reducing negative outcomes.
Full text links
Related Resources
Trending Papers
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app